title: Fatal disseminated Acanthamoeba infection in a liver transplant recipient immunocompromised by combination therapies for graft-versus-host disease.
abstract: Immunosuppressed solid organ transplant recipients are at increased risk for acquisition of opportunistic pathogens, with potentially fatal consequences. With the introduction of novel immunosuppressive agents used to prevent organ rejection and to treat the sequelae of transplantation, severity and rates of infection with unusual opportunistic pathogens may increase. Various monoclonal antibodies are now being used in the treatment of severe, acute graft-versus-host disease (GVHD), including rituximab, daclizumab, and alemtuzumab. These therapies, particularly when used in combination and with other traditional forms of immunosuppression, may have profound effects on the immune system. Acanthamoeba species are ubiquitous, free-living protozoa that rarely cause disseminated disease in the immunocompromised host. We report a fatal case of disseminated Acanthamoeba infection with a dramatic cutaneous presentation in a liver transplant recipient severely immunocompromised by sequential standard and novel therapies used to successfully treat life-threatening acute GVHD. This case illustrates the current major limitation of these therapies, discusses the cutaneous findings in disseminated acanthamoebiasis, and highlights the need to maintain vigilance for the presence of unusual infection in patients receiving similar therapeutic regimens.
authors.affiliation: Department of Dermatology, Columbia University Medical Center, New York, New York, USA. aly1@columbia.edu
authors.forename: A L
authors.initials: AL
authors.lastname: Young
authors.forename: N R
authors.initials: NR
authors.lastname: Leboeuf
authors.forename: S J
authors.initials: SJ
authors.lastname: Tsiouris
authors.forename: S
authors.initials: S
authors.lastname: Husain
authors.forename: M E
authors.initials: ME
authors.lastname: Grossman
mesh_terms: D000048:Acanthamoeba / Q000472:pathogenicity*; D000562:Amebiasis / Q000469:parasitology / Q000473:pathology*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D006084:Graft Rejection / Q000517:prevention & control; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012876:Skin Diseases, Parasitic / Q000469:parasitology / Q000473:pathology*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents